Innovent announces it has signed a licensing agreement with PT Etana Biotechnologies for Byvasda® (biosimilar bevacizumab). Under the agreement, Etana will receive commercialisation rights in Indonesia in exchange for milestone payments and double-digit royalties on net sales.
Product specific reports based on extracts from our BioBlast™ database
BioBlast™ Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast™ sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast™ to recieve our updates via email.